the vaccine , developed in canada , is based on an animal virus called vesicular stomatitis virus ( vsv ) that is combined with a portion of the protein covering of the ebola virus . he added : ' just one vaccine has conferred one hundred per cent protection against ebola in the initial trials on primates . ' in the phase ii studies that are now beginning , the vaccine will be used in patients living in the areas currently most badly affected by ebola , especially guinea and sierra leone , but also in liberia .